Nurix Therapeutics (NRIX)

• Market cap: $1.41B
• 1 day: -1.90%
• 5 days: -4.96%
• 1 month: -3.28%
• 3 months: -25.76%
• 6 months: -10.32%
• Year to date: -4.72%
• 1 year: 121.05%
• 5 years: -2.21%
• 10 years: -2.21%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Employees: 286

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

52% more call options, than puts

Call options by funds: $1.84M | Put options by funds: $1.21M

14% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 57

9% more capital invested

Capital invested by funds: $1.4B [Q2] → $1.52B (+$121M) [Q3]

3% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 30

1% less funds holding

Funds holding: 173 [Q2] → 171 (-2) [Q3]

7.98% less ownership

Funds ownership: 112.99% [Q2] → 105.01% (-7.98%) [Q3]

25% less funds holding in top 10

Funds holding in top 10: 4 [Q2] → 3 (-1) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $17 9% downside
• Avg. target: $31 64% upside
• High target: $36 94% upside

9 analyst ratings

• positive: 8 89%
• neutral: 1 11%
• negative: 0 0%

Morgan Stanley Terence Flynn 53% 1-year accuracy 9 / 17 met price target	9% downside $17	Equal-Weight Maintained	3 Feb 2025
RBC Capital Gregory Renza 39% 1-year accuracy 34 / 88 met price target	45% upside $27	Outperform Maintained	29 Jan 2025
JP Morgan Eric Joseph 48% 1-year accuracy 14 / 29 met price target	61% upside $30	Overweight Maintained	29 Jan 2025
Stifel Stephen Willey 59% 1-year accuracy 10 / 17 met price target	94% upside $36	Buy Maintained	29 Jan 2025
Needham Gil Blum 19% 1-year accuracy 32 / 171 met price target	51% upside $28	Buy Maintained	29 Jan 2025